🔥 TOGETHER-PsA (OP069) #EULAR2026 #EULARbest Ixekizumab + Tirzepatide vs IXE alone in PsA with obesity/overweight: ✅ Primary endpoint (ACR50 + ≥10% wt loss at W36): 31.7% vs. 0.8% (p<0.001) ✅ ACR50: 33.5% vs. 20.4% ✅ MDA: 26.3% vs. 15.3% (p=0.026) @rheumnow @DrLauraCoates https://t.co/6wh3S6khXw

• https://x.com/Nellziade/status/2062565805594755234/photo/1

🔬 Can baseline T cell phenotype predict PsA treatment response? COLIPSO cohort (n=17): YES! Higher Treg & activated CD4+ cells predict DAPSA & joint improvement #POS0083 #EULAR2026 @RheumNow https://t.co/UIs6LXAWAY

• https://x.com/Nellziade/status/2062550185796890781/photo/1

⚖️ Does BMI outrank treatment in early PsA outcomes? YES - SPEED trial AI analysis: BMI #1 predictor of PASDAS at 1yr in 192pts #OP0187 #EULAR2026 @RheumNow https://t.co/9cZG7AWau2

• https://x.com/Nellziade/status/2062543928293839328/photo/1

💉 Does bimekizumab work in real-world PsA? YES - EuroSpA: 76% retention at 6months 46% DAPSA LDA in 787pts across 12 registries #OP0185 #EULAR2026 @RheumNow https://t.co/TXS3r9mZXB

• https://x.com/Nellziade/status/2062543554623291769/photo/1

🧲 Does GUS+GOL combo beat GUS alone on MRI in PsA? YES for joints - AFFINITY Phase 2a RCT: greater MRI inflammation reduction in 91pts #OP0186 #EULAR2026 @RheumNow https://t.co/9eIS6lh7WN

• https://x.com/Nellziade/status/2062542859106910588/photo/1

🧬 Do biomarkers predict #zasocitinib response in PsA? YES: TYK2/IL-17 pathway markers predict ACR20 in 290pts Phase 2b RCT #OP0184 #EULAR2026 @RheumNow https://t.co/AVlyrauI5q

• https://x.com/Nellziade/status/2062542434538602642/photo/1

🔎 Can US predict PsA progression from psoriasis? YES: synovio-entheseal inflammation predicts progression in 183pts prospective cohort #OP0183 #EULAR2026 @RheumNow https://t.co/7B9KU60qFd

• https://x.com/Nellziade/status/2062542104539037964/photo/1

🦴 What drives enthesophytes in PsA? SITE-SPECIFIC: Pelvic driven by disease activity+BMI Calcaneal by BMI+damage in a 1596pts cohort OP0182 #EULAR2026 @RheumNow https://t.co/4RxgjJ2V9u

• https://x.com/Nellziade/status/2062541622307385396/photo/1

❤️ Do biologics differ in MACE risk in PsA? YES - JAKi highest risk after 2.5yrs vs TNFi/IL-17i/IL-23i in a retrospective cohort of 22,246pts. OP0181 #EULAR2026 @RheumNow https://t.co/eQdBtMfRAY

• https://x.com/Nellziade/status/2062541174926172225/photo/1

After TNFi secondary failure: does MOA switch beat TNFi cycling? UK RWD (n=155): yes for #PsA (76% vs 57% drug survival at 12m) and axSpA (80% vs 68%), but not RA. Yet 74% of axSpA pts still got another TNFi. Evidence vs practice gap in plain sight. @RheumNow #EULAR2026 POS0776

Real-world bimekizumab in SpA/#PsA (BIMPACT, n=223): 76% retention at 12mo, even with 54% having prior IL-17i exposure. Effective after IL-17Ai failure. Oral candidiasis higher in PsA (16.5%) vs SpA (3.3%); led to discontinuation in ~25%. @RheumNow #EULAR2026 POS0798/POS0810

Impt pts to consider in D2T CLE by Prof Wittmann: If tx is not working, ask yourself: is the dx correct? adherence? Main message: treat early When damage is present, tx doesn’t really provide considerable improvements Future drxns? Endotype-directed tx @Rheumnow #EULAR2026 https://t.co/hB48aD7jx5

• https://x.com/RHEUMarampa/status/2062483851641819613/photo/1
• https://x.com/RHEUMarampa/status/2062483851641819613/photo/1

💉 Is Izokibep (Novel IL-17i) durable in PsA at 1yr? Phase2b/3 RCT: ~50% ACR50 at week in 343pts OP073 #EULAR2026 @RheumNow https://t.co/M3nrKFTA7c

• https://x.com/Nellziade/status/2062265661829611550/photo/1

🔬 Does synovial biopsy-guided treatment outperform standard care in PsA? YES - 68% vs 45% DAPSA remission/LDA in 45pts OP071 #EULAR2026 @RheumNow https://t.co/cLCR7I8QAm

• https://x.com/Nellziade/status/2062264618098065814/photo/1